Rating Change
Laidlaw & Co. analysts initiated coverage on Kadimastem Ltd (NASDAQ:NCEL) with a Buy rating on July 13, 2026.
new coverageNASDAQ:NCEL
Laidlaw & Co. Initiates Coverage on Kadimastem Ltd (NCEL) with Buy
Rating Change Laidlaw & Co. analysts initiated coverage on Kadimastem Ltd (NASDAQ:NCEL) with a Buy rating on July 13, 2026. Market Context Kadimastem Ltd operates in the…
Market Context
Kadimastem Ltd operates in the Healthcare sector. The stock currently trades at $3.92 with a market capitalization of $1.5M.
Analyst coverage from Laidlaw & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Kadimastem Ltd.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Kadimastem Ltd
Among the 1 most recent ratings: 1 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | Laidlaw & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NCEL Stock Page
Frequently Asked Questions
What does a Buy rating mean for NCEL?
A Buy rating from Laidlaw & Co. reflects the analyst's outlook on Kadimastem Ltd (NASDAQ:NCEL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NCEL forecast page.